# A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

> **NCT02637531** · PHASE1 · UNKNOWN · sponsor: **Infinity Pharmaceuticals, Inc.** · enrollment: 219 (actual)

## Conditions studied

- Advanced Solid Tumors (Part A/B/C/D)
- Non-small Cell Lung Cancer (Part E)
- Melanoma (Part E)
- Squamous Cell Cancer of the Head and Neck (Part E)
- Triple Negative Breast Cancer (Part F)
- Adrenocortical Carcinoma (Part G)
- Mesothelioma (Part G)
- High-circulating Myeloid-derived Suppressor Cells (Part H)

## Interventions

- **DRUG:** IPI-549 (eganelisib)
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02637531
- **Lead sponsor:** Infinity Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2022-01
- **Final completion:** 2022-12
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02637531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02637531, "A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02637531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*